Project Number 1R01AG074983-01 Agency/Funding Organization NIA Funding Year 2022 View Full Project Details for Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) a. Amyloid beta Researcher and Organization Principal Investigator AGADJANYAN, MICHAEL G Principal Investigator First Name MICHAEL G Principal Investigator Last Name AGADJANYAN Awardee Organization INSTITUTE FOR MOLECULAR MEDICINE Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-18-877: Early Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional) FY Overall Cost $2,680,709 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official CLARKE, AKANNI YAO
